Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
22 févr. 2021 08h30 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update
05 nov. 2020 16h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the...
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
23 sept. 2020 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study (NCT03335371) that support the...
vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
16 sept. 2020 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral...
vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
27 juil. 2020 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International...
vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions
27 mai 2020 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive...
vTv Therapeutics Announces 2020 First Quarter Financial Results and Update
07 mai 2020 16h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020, and provided an update on recent...
vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
20 févr. 2020 18h57 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an...
Insulin Market To Reach USD 35.74 Billion By 2027| Reports And Data
13 janv. 2020 09h33 HE
|
Reports and Data
New York, Jan. 13, 2020 (GLOBE NEWSWIRE) -- The global Insulin Market is forecast to reach USD 35.74 Billion by 2027, according to a new report by Reports and Data. Insulin therapy is used for the...
NobleCon Investor Conference: Country Star Eric Paslay Joins Type 1 Diabetes Panel Presentation Entitled “A Functional Cure Could Be Imminent”
10 déc. 2019 12h41 HE
|
Noble Financial Group, Inc.
FORT LAUDERDALE, Fla., Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Noble Capital Markets, Inc. (“Noble”) announced today that country star Eric Paslay (with hits like “Friday Night”) will...